Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Amsterdam : Elsevier
    Journal of Psychosomatic Research 37 (1993), S. 355-360 
    ISSN: 0022-3999
    Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics: Medicine , Psychology
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    Amsterdam : Elsevier
    Biochemical and Biophysical Research Communications 154 (1988), S. 380-386 
    ISSN: 0006-291X
    Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics: Biology , Chemistry and Pharmacology , Physics
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    ISSN: 1432-0428
    Keywords: Biguanide (metformin) ; obesity ; non-ketotic diabetes ; Schilling-test ; d-xylose-test ; intestinal absorption ; blood lipids
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Résumé Chez 21 patients atteints de diabète sucré clinique ou chimique et d'obésité, on a déterminé l'excrétion urinaire de vitamine B12 et de D-xylose, ainsi que les taux de lipides sanguins, avant et après un traitement de 10 jours à la metformine. En outre, des études de la tolérance aux graisses et du bilan lipidique ont été effectuées chez 7 patients. Au cours d'une étude prolongée de 9 patients, le test de Schilling a été répété 2–3 mois après le début du traitement à la metformine chez a) 7 patients sous traitement permanent à la metformine, et b) 2 patients après cessation du traitement initial à la metformine. Les résultats étaient les suivants: l'absorption de vitamine B12 et de D-xylose était pathologiquement basse après traitement à la metformine. Les lipides sanguins et le poids corporel étaient réduits. Il y avait également certains signes de trouble de l'absorption des graisses, qui n'ont pas pu cependant être démontrés. D'après nos résultats, il est possible que la chute de la glycémie après le traitement à la. metformine, soit en partie provoquée par une mauvaise absorption du glucose. L'opinion de Sadow concernant l'effet de la metformine sur le métabolisme des hydrates de carbone doit donc être reconsidérée. Les implications cliniques de ces résultats, particulièrement en ce qui concerne l'absorption de la vitamine B12 sont discutées.
    Abstract: Zusammenfassung Bei 21 Patienten wurden vor und 10 Tage nach Biguanidtherapie die Vitamin B12- und Xyloseausscheidung im Urin, sowie die Blutlipide bestimmt. Bei 7 Patienten wurden zusätzlich eine Fettbilanzstudie und ein Fettbelastungstest vor und während Biguanidtherapie durchgeführt. Bei 5 Patienten wurde der Schillingtest 2–3 Monate nach Beginn der Biguanidtherapie erneut bestimmt, bei 2 Patienten zur gleichen Zeit nach Absetzen der initialen Therapie. Die Resultate sind folgende: Vitamin B12- und Xyloseabsorption sind während der Biguanidtherapie pathologisch erniedrigt, der Schillingtest kann sich nach der Langzeittherapie normalisieren. Die Blutlipide und das Körpergewicht fallen nach 10-tägiger Therapie ab. Die Resultate lassen auch eine Fettabsorptionsstörung vermuten. Die Ergebnisse berechtigen zur Annahme, daß die Blutzuckersenkung nach Biguanidtherapie z.T. ebenfalls die Folge einer Absorptionsstörung ist und sprechen dafür, daß das Konzept über die Wirkungsweise der Biguanide von Sadow, welches in der Einleitung besprochen wird, in diesem Sinne erweitert werden muß. Die sich für die Klinik ergebenden Konsequenzen dieser biguanidbedingten Absorptionsstörung, insbesondere auch von Vitamin B12 werden diskutiert.
    Notes: Summary Urinary excretion of vitamin B12 and D-xylose, and the levels of blood lipids were determined in 21 patients with clinical or chemical diabetes mellitus and obesity, before and 10 days after metformin treatment. In addition, fat tolerance and fat balance studies were carried out in 7 patients. In a long term study of 9 patients, the Schilling test was repeated 2–3 months after the beginning of the metformin treatment in a) 7 patients with permanent metformin treatment, and b) 2 patients after cessation of initial metformin treatment. The results were as follows: vitamin B12 and D-xylose absorptions were pathologically low after metformin treatment. Blood lipids and body weight were reduced. There was also some indication of disturbed fat absorption, which, however, could not be proved. Based on our results, it is possible that the decrease in blood sugar after treatment with metformin is partly induced by malabsorption of glucose. Thus the concept of Sadow on the effect of metformin on carbohydrate metabolism has to be reëvaluated. The clinical implications of the results, especially with respect to vitamin B12 absorption are discussed.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    ISSN: 1432-1041
    Keywords: bopindolol ; hypertension ; beta-blocker ; blood pressure ; plasma renin ; plasma catecholamines
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary Bopindolol (LT 31-200), a new, long-acting, non-selective beta-blocker, was given as monotherapy to 13 patients, 12 with essential hypertension and 1 with renovascular hypertension. After a placebo period of 4–6 weeks, bopindolol was given once daily, starting with 1 mg and subsequently increasing at two-weekly intervals to 2 and 4 mg once daily until a diastolic blood pressure⩽90 mmHg was achieved. The effective dose was continued for 12 weeks. In 10 patients plasma levels of renin, noradrenaline, adrenaline and cholesterol were measured during placebo and after 3 months of therapy. Blood pressure and heart rate were lowered significantly during bopindolol treatment. The mean effective dose was 2.2 mg per day. In 10/13 patients a diastolic blood pressure⩽90 mmHg was achieved. Side effects were minimal. Changes in plasma noradrenaline and adrenaline were small and not significant, but renin and cholesterol were significantly reduced. Thus, LT 31-200 is an effective and well tolerated beta-blocker when given in a once daily dosage.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...